Similar Search Results

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10012481677

Aghion, Philippe; Bergeaud, Antonin; Van Reenen, John - National Bureau of Economic Research - 2021

Does regulation affect the pace and nature of innovation and if so, by how much? We build a tractable and quantifiable … sharp reduction in the firm's innovation response to exogenous demand shocks for firms just below the regulatory threshold …. We then quantitatively fit the parameters of the model to the data, finding that innovation at the macro level is about 5 …

Persistent link: https://www.econbiz.de/10012482599

Moonshot : Public R&D and Growth

Kantor, Shawn Everett; Whalley, Alexander T. - National Bureau of Economic Research - 2023

We estimate the long-term effect of public R&D on growth in manufacturing by analyzing new data from the Cold War era Space Race. We develop a novel empirical strategy that leverages US-Soviet rivalry in space technology to isolate windfall R&D spending. Our results demonstrate that public R&D...

Persistent link: https://www.econbiz.de/10014322858

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677

Monetary Policy and Innovation

Ma, Yueran; Zimmermann, Kaspar - National Bureau of Economic Research - 2023

We document that monetary policy has a substantial impact on innovation activities. After a tightening shock of 100 …-based aggregate innovation index, declines by up to 9 percent in the following 2 to 4 years. Based on previous estimates of the … sensitivity of output to innovation activities, these magnitudes imply that output could be 1 percent lower after another 5 years …

Persistent link: https://www.econbiz.de/10014372455

Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?

D'Souza, Arielle; Hoyt, Kendall; Snyder, Christopher M.; … - National Bureau of Economic Research - 2024

Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...

Persistent link: https://www.econbiz.de/10015056157

Return on Returns : Building Scientific Capacity in AIDS Endemic Countries

Fry, Caroline; Ganguli, Ina - National Bureau of Economic Research - 2023

We estimate spillovers from public funding for health research in the context of the NIH's Fogarty International Center's AIDS International Training and Research Program, which aims to strengthen scientific capacity in AIDS endemic countries by providing African researchers with training...

Persistent link: https://www.econbiz.de/10014322762

The Role of Assets In Place : Loss of Market Exclusivity and Investment

Higgins, Matthew J. - 2020

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10012481442

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice C.; Krieger, Joshua L.; … - National Bureau of Economic Research - 2021

Investment in intangible capital--in particular, research and development--increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10012482573

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A. - 2005

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10012466796